They have multiple product candidates in development, including reproxalap, a first-in-class treatment for dry eye disease and allergic conjunctivitis.. Aldeyra's approach is to develop therapies that modulate immunological systems, with the goal of optimizing multiple pathways at once while minimizing toxicity.. Two of their lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP.. Reproxalap is in Phase 3 clinical trials, and ADX-629 is in Phase 2 proof-of-concept clinical trials.. Aldeyra's pipeline also includes ADX-2191, in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.